[Memorandum Opinion and Order, Peter Lurie, plaintiff v. Department of the Army, defendant]

)

was a bunt down the foul line.' "); 257 Science, at 605 (July 31, 1992) ("Robert Redfield
of the Walter Reed Army Institute of Research claimed that he's reduced the amount of
HIV in the blood cells of infected people who have been treated for two years with a
vaccine made from the HIV surface protein gp160."). In the same article, the Boston
Globe reported on the Army's program and the pressure for its expansion:
The U.S. Army is spending $15 million on a trial in
progress of GP-160 compared with a dummy vaccine in 600
H.I.V.-infected patients. Studies so far, which indicate GP160 is apparently harmless are generating pressure by AIDS
activists and doctors to let the experimental vaccine be tried
in a bigger group, perhaps 2,000 HIV-infected volunteers
while waiting for definitive evidence.
"Can we let the next three years go by without some
kind of wider acceptance to GP-160?" said Dr. Calvin Cohen
of Boston, research director of the Community Research
Initiative of New England. "Clinical researchers like me need
to meet with the Food and Drug Administration and try to
make it happen."
Knox, New Problems, New Hopes at AIDS Pdrley, supra.
On September 18, 1992, Senator Sam Nunn introduced Amendment No. 3094 to
the bill that became the 1993 National Defense Authorization Act. This amendment
provided $20 million for further testing of gp160:
Mr. President, I offer this amendment that would add
$20 million for AIDS and research at the Department of
Defense medical research facilities.
This amendment would provide for the third phase of
testing for a new vaccine which has shown great promise as a
way of delaying the onset of the deadly implications of the
AIDS virus. This advantage is now seen in stage 2 testing in